Skip to main content
Fig. 3 | BMC Pulmonary Medicine

Fig. 3

From: Abediterol, a novel long-acting β2-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD

Fig. 3

Change from baseline in trough FEV1 at Day 2 (per-protocol population). ****p < 0.0001 vs placebo; ††††p < 0.0001 vs indacaterol. Data reported as LS mean difference from placebo (ANCOVA) ± SE. ANCOVA, analysis of covariance; FEV1, forced expiratory volume in 1 s; LS, least squares; SE, standard error

Back to article page